[go: up one dir, main page]

WO2002003071A3 - Modulateurs de l'activite de la proteine trk, et compositions et methodes d'utilisation - Google Patents

Modulateurs de l'activite de la proteine trk, et compositions et methodes d'utilisation Download PDF

Info

Publication number
WO2002003071A3
WO2002003071A3 PCT/US2001/021472 US0121472W WO0203071A3 WO 2002003071 A3 WO2002003071 A3 WO 2002003071A3 US 0121472 W US0121472 W US 0121472W WO 0203071 A3 WO0203071 A3 WO 0203071A3
Authority
WO
WIPO (PCT)
Prior art keywords
trk
compositions
trk protein
modulators
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/021472
Other languages
English (en)
Other versions
WO2002003071A2 (fr
Inventor
Alan Thomas Bates
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pangene Corp
Original Assignee
Pangene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pangene Corp filed Critical Pangene Corp
Priority to AU2001273245A priority Critical patent/AU2001273245A1/en
Publication of WO2002003071A2 publication Critical patent/WO2002003071A2/fr
Anticipated expiration legal-status Critical
Publication of WO2002003071A3 publication Critical patent/WO2002003071A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Food Science & Technology (AREA)
  • Psychiatry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention porte sur des tyrosine kinases réceptrices et les ligands à cet effet modulant la croissance, la différentiation et la survie des cellules. Elle porte particulièrement sur la famille Trk des tyrosine kinases réceptrices connues pour médier les activités des neurotrophines, les protéines Trk étant également des proto-oncogènes connus; sur des compositions de petites molécules modulant la fixation et l'activité de la protéine Trk; et sur des procédés de criblage de petites molécules pouvant se fixer à la protéine Trk en se fixant à un ou plusieurs de ses déterminants de fixation à la neurotrophine.
PCT/US2001/021472 2000-07-05 2001-07-05 Modulateurs de l'activite de la proteine trk, et compositions et methodes d'utilisation Ceased WO2002003071A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001273245A AU2001273245A1 (en) 2000-07-05 2001-07-05 Modulators of trk protein activity, compositions and uses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21577800P 2000-07-05 2000-07-05
US60/215,778 2000-07-05

Publications (2)

Publication Number Publication Date
WO2002003071A2 WO2002003071A2 (fr) 2002-01-10
WO2002003071A3 true WO2002003071A3 (fr) 2003-01-30

Family

ID=22804345

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/021472 Ceased WO2002003071A2 (fr) 2000-07-05 2001-07-05 Modulateurs de l'activite de la proteine trk, et compositions et methodes d'utilisation

Country Status (2)

Country Link
AU (1) AU2001273245A1 (fr)
WO (1) WO2002003071A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196061B2 (en) * 2003-09-10 2007-03-27 Wyeth Compounds that modulate neuronal growth and their uses
CN1897977A (zh) * 2003-10-20 2007-01-17 Ns基因公司 帕金森氏病的体内基因治疗
JP2008029296A (ja) * 2006-07-31 2008-02-14 Hisamitsu Pharmaceut Co Inc 神経芽種の治療薬及びそのスクリーニング方法、並びに、神経芽種の予後の判定方法
KR102709884B1 (ko) 2017-11-30 2024-09-26 리제너론 파마슈티칼스 인코포레이티드 인간화된 trkb 유전자좌를 포함하는 비인간 동물
WO2022009992A1 (fr) * 2020-07-10 2022-01-13 国立大学法人東京大学 Peptide cyclique, complexe peptidique et composition médicamenteuse contenant ledit peptide cyclique et/ou ledit complexe peptidique

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622862A (en) * 1991-04-23 1997-04-22 Regeneron Pharmaceuticals, Inc. Assay systems for trkB neurotrophin activity
WO1999033482A1 (fr) * 1997-12-31 1999-07-08 University Of Utah Research Foundation Utilisation de peptides alpha-conotoxines

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622862A (en) * 1991-04-23 1997-04-22 Regeneron Pharmaceuticals, Inc. Assay systems for trkB neurotrophin activity
WO1999033482A1 (fr) * 1997-12-31 1999-07-08 University Of Utah Research Foundation Utilisation de peptides alpha-conotoxines

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
URFER R ET AL: "AN IMMUNOGLOBULIN-LIKE DOMAIN DETERMINES THE SPECIFICITY OF NEUROTROPHIN RECEPTORS", EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 14, no. 12, 15 June 1995 (1995-06-15), pages 2795 - 2805, XP000568880, ISSN: 0261-4189 *
WINDISCH J M ET AL: "BRAIN-DERIVED NEUROTROPHIC FACTOR, NEUROTROPHIN-3, AND NEUROTROPHIN-4 BIND TO A SINGLE LEUCINE-RICH MOTIF OF TRKB", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, PA, US, vol. 34, no. 35, 5 September 1995 (1995-09-05), pages 11256 - 11263, XP002062138, ISSN: 0006-2960 *

Also Published As

Publication number Publication date
AU2001273245A1 (en) 2002-01-14
WO2002003071A2 (fr) 2002-01-10

Similar Documents

Publication Publication Date Title
WO1998024432A3 (fr) Utilisation de composes a base d'indolinone en tant que modulateurs de proteine kinases
AU3801997A (en) Assays for protein kinases using fluorescent protein substrates
WO2008028168A3 (fr) Sérine-thréonine protéine kinase et modulateurs parp
MX9604316A (es) Anticuerpos agonistas de la proteina tirosina cinasa.
EP2409704A3 (fr) Modulateurs c-Met et procédés d'utilisation
AU1756601A (en) Dye labeled imidazoquinoline compounds
WO2005020921A3 (fr) Modulateurs c-kit et leurs procedes d'utilisation
DE69738930D1 (de) Methoden zur modulation der melaninsynthese
AU2003209636A1 (en) Novel chemokine binding peptides capable of modulating the biological activity of chemokines
WO2000048621A3 (fr) Techniques et compositions permettant de reguler les interactions de proteine a proteine
WO2005016966A3 (fr) Proteines hybrides a intron et procede d'identification et d'utilisation de celles-ci
GEP20043349B (en) Methods of Controlling Cutworm Pests
WO2001023412A3 (fr) Procedes de criblage d'agents inhibiteurs de l'agregation des polypeptides
WO2002065134A3 (fr) Procedes et agents de criblage
WO2002003071A3 (fr) Modulateurs de l'activite de la proteine trk, et compositions et methodes d'utilisation
WO2002002751A3 (fr) Alteration des membranes cellulaires en vue d'obtenir de nouvelles fonctions
WO2002005843A3 (fr) Sequences rrp humaines et procedes d'utilisation
WO2003020892A3 (fr) Acides nucleiques et polypeptides bv8 a activite mitogene
GB2322132B (en) Keratinocyte growth factor-2 products
WO2001009326A9 (fr) Facteurs de transcription structurellement actifs et leurs utilisations pour identifier les modulateurs d'activite y compris les modifications cellulaires dysproliferatives
WO2002092765A3 (fr) Nouveaux inhibiteurs de la telomerase et utilisations correspondantes
AU762955C (en) Methods and compositions useful for modulation of angiogenesis using tyrosine kinase SRC
WO2002053726A3 (fr) Interactions proteine-proteine dans des cellules adipeuses
WO2002026929A3 (fr) Proteine moteur kini-3 et methodes d'utilisation associees
WO2002026960A3 (fr) Modulation de l'expression genique au moyen de domaines de localisation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP